Daniela Salvemini, Ph.D., Professor of Pharmacology & Physiology published a paper in Pain detailing her studies on chemotherapy induced neuropathic pain (CINP) caused by a treatment used for colorectal cancer.

A common platinum-based chemotherapy drug, oxaliplatin, used to treat colorectal cancer causes CINP in over 60% of patients. Using an animal model, investigators found that the pain was caused by an increased expression of adenosine kinase in astrocytes and decreased adenosine signaling at the A3AR receptor. They used A3AR agonists to increase signaling, which blocked the pain without interfering with the efficacy of the anticancer treatment. A3AR agonists are already being evaluated in clinical trials as anticancer agents, and could be readily available for use in conjunction with oxaliplatin treatment.

For more information, read the full article in Newslink.